Sugi Predict

Sugi Predict / Compounds / SCHEMBL4081612

SCHEMBL4081612

SCHEMBL4081612

O=C(O)CCNC(=O)c1ccc(C(NC(=O)Nc2ccc3[nH]ccc3c2)c2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.47
▸ EPHX2 P34913 2/20 0.43
▸ GCGR P47871 4/20 0.43
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TRPV1 Q8NER1 1/20 0.40
▸ EGLN2 Q96KS0 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ HDAC3 O15379 2/20 0.38
▸ HDAC11 Q96DB2 2/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ HDAC6 Q9UBN7 2/20 0.38
▸ DEGS1 O15121 1/20 0.38
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6754090 0.83 EPHX2 (0.45) EPHX2GCGRNPC1MAPTCYP2D6
SCHEMBL2653167 0.82 GCGR (0.46) EPHX2GCGRCYP2D6HDAC3HDAC11
SCHEMBL4081733 0.82 EPHX2 (0.45) EPHX2GCGRTRPV1CYP2D6HDAC3
SCHEMBL4096042 0.82 GCGR (0.49) EPHX2GCGRCYP2D6
SCHEMBL6750387 0.82 GCGR (0.50) EPHX2GCGRCYP2D6HDAC3HDAC11
SCHEMBL2653146 0.82 GCGR (0.50) EPHX2GCGRNPC1MAPTCYP2D6
SCHEMBL2652582 0.82 GCGR (0.51) EPHX2GCGRCYP2D6HDAC3HDAC11
SCHEMBL2652649 0.82 GCGR (0.50) EPHX2GCGRNPC1RAB9ACYP2D6
SCHEMBL2651718 0.82 GCGR (0.50) EPHX2GCGRNPC1RAB9AMAPT
SCHEMBL2650399 0.82 GCGR (0.50) EPHX1EPHX2GCGRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR EPHX1 2751/4885EPHX2 3463/4885GCGR 3/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR EPHX1 2751/4885EPHX2 3463/4885GCGR 3/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR EPHX1 2751/4885EPHX2 3463/4885GCGR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.